Skip to content

Safety and Efficacy of WZ-6600 Nasal Drops in the Treatment of Traumatic Optic Neuropathy: A Multicenter, Randomized, Controlled Trial

Safety and Efficacy of WZ-6600 Nasal Drops in the Treatment of Traumatic Optic Neuropathy: A Multicenter, Randomized, Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600125329
Enrollment
Unknown
Registered
2026-05-25
Start date
2026-06-01
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Traumatic Optic Neuropathy (TON)

Interventions

Group B:WZ-6600 Nasal Drops
Group A:WZ-6600 Nasal Drops + Endoscopic Transnasal Optic Canal Decompression (ETOCD)
Group C:Placebo Nasal Drops + Endoscopic Transnasal Optic Canal Decompression (ETOCD)
Group D:Placebo Nasal Drops

Sponsors

Eye Hospital, Wenzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
12 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. Meeting the diagnostic criteria for TON; 2. Unilateral traumatic optic neuropathy; 3. BCVA of the injured eye ranging from 0.02 to 0.3 (decimal visual acuity); 4. Time since injury less than 3 months; 5. Aged between 12 and 45 years old; 6. Patients who fully understand the safety profile of the study, are willing to actively cooperate with the research, and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Complicated with craniocerebral trauma or history of craniocerebral surgery; 2. Cerebral tumors or cerebrovascular diseases; 3. Complicated with severe systemic diseases, such as poorly controlled hypertension, poorly controlled diabetes mellitus, or autoimmune diseases; 4. History of previous ophthalmic surgery; 5. Presence of ocular disorders that may affect visual function, including corneal ulcer, cataract, retinal vascular diseases, retinal detachment, and other optic nerve diseases; 6. History of genetic diseases; 7. History or family history of neurological diseases or psychiatric disorders; 8. Severe major systemic diseases such as cardiac, hepatic, or renal insufficiency; 9. Pregnant, lactating women, or women with plans for pregnancy within the next 6 months; 10. Participation in other clinical trials within the past 6 months.

Design outcomes

Primary

MeasureTime frame
Best-Corrected Visual Acuity;

Secondary

MeasureTime frame
Macular Vascular Density;Macular Retinal Thickness;Visual Evoked Potential(VEP);Visual Field;Optic Disc Vascular Density;Ganglion Cell Complex Thickness;Retinal Nerve Fiber Layer Thickness;

Countries

China

Contacts

Public ContactWu Wencan

Eye Hospital, Wenzhou Medical University

wuwencan118@163.com+86 577 81152625

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026